DexCom SVP Andrew K. Balo Sells 10,000 Shares (DXCM)
DexCom (NASDAQ:DXCM) SVP Andrew K. Balo sold 10,000 shares of the company’s stock on the open market in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.12, for a total value of $441,200.00. Following the transaction, the senior vice president now directly owns 159,205 shares in the company, valued at approximately $7,024,125. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of DexCom (NASDAQ:DXCM) traded down 1.55% during mid-day trading on Wednesday, hitting $45.18. The stock had a trading volume of 663,270 shares. DexCom has a one year low of $25.49 and a one year high of $49.83. The stock’s 50-day moving average is $40.11 and its 200-day moving average is $39.03. The company’s market cap is $3.410 billion.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.
A number of analysts have recently weighed in on DXCM shares. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $41.00.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.